The virus has different surface proteins that existing vaccines cannot recognize
In the Democratic Republic of the Congo and Uganda, an Ebola outbreak has revealed a quiet but consequential gap in humanity's medical defenses: the vaccines we built do not match the virus now spreading. The Bundibugyo strain, distinct from the Zaire virus that existing shots were designed to fight, has claimed dozens of lives and exposed how narrowly our preparedness can be calibrated. Now, with $62 million in new funding, three scientific teams are racing to close that gap — each carrying a different technological approach, each still months or years from the arms of those most at risk.
- Existing approved Ebola vaccines are biologically mismatched to the Bundibugyo strain killing people in DRC and Uganda, leaving frontline responders without a targeted immunological tool.
- Over 350 confirmed cases and 61 deaths have been recorded across both countries, sustaining pressure on health systems already stretched thin in remote, resource-limited regions.
- Three vaccine candidates — from IAVI, Moderna, and Oxford/Serum Institute — are advancing on parallel tracks, backed by fresh emergency funding, but none are closer than two months from even beginning human trials.
- The WHO has flagged the IAVI single-dose candidate as the most promising, with macaque data already in hand, though human trials remain seven to nine months out.
- Beyond the science, the road to deployment is lined with compounding obstacles: clinical recruitment, regulatory hurdles, manufacturing scale-up, and delivery into the very outbreak zones where logistics and security are most fragile.
The DRC and Uganda are confronting an Ebola outbreak that the world's existing vaccines cannot address. By early June, the DRC had confirmed 344 cases and 60 deaths from Bundibugyo Ebola virus; Uganda reported 15 cases and one death. The numbers, while lower than earlier feared, underscore a critical vulnerability: the two approved Ebola vaccines, Ervebo and Zabdeno/Mvabea, were built to fight the Zaire strain. The Bundibugyo virus carries different surface proteins, and those vaccines simply do not recognize it.
In response, the Coalition for Epidemic Preparedness Innovations announced up to $62 million in funding to accelerate three distinct vaccine candidates. The International AIDS Vaccine Initiative, partnering with the University of Texas Medical Branch, has developed a single-dose shot using technology similar to Ervebo. It has already protected macaques against Bundibugyo infection, and a WHO expert panel called it the most promising of the three — though human trials are still seven to nine months away. Moderna is applying its mRNA platform, targeting the virus's surface glycoprotein, with funding now supporting both animal and early human studies. The University of Oxford and the Serum Institute of India are furthest behind, having only just begun testing, but the WHO panel suggested human trials could open within two to three months if animal data holds.
Each candidate still faces the full gauntlet of drug development: proving safety and efficacy in humans, securing regulatory approval, scaling manufacturing, and delivering doses into regions that are often remote and under-resourced. Late-stage trials, by necessity, must be conducted near the outbreak itself — where logistical and security challenges are most acute and where vaccine misinformation can complicate recruitment.
For now, the outbreak is being managed through isolation, contact tracing, and protection of healthcare workers. A targeted vaccine would be transformative — not only for this outbreak but for any future emergence of Bundibugyo. The funding is committed and the science is moving. What lies ahead is the slower, harder work of turning laboratory promise into a tool that can reach the people who need it most.
The Democratic Republic of the Congo and Uganda are facing an outbreak of a virus that existing Ebola vaccines cannot stop. As of early June, health authorities in the DRC had confirmed 344 cases and 60 deaths from Bundibugyo Ebola virus, while Uganda reported 15 confirmed cases and one death. The numbers represent a significant downgrade from earlier estimates that had suggested more than 1,000 suspected cases in the region, but the outbreak remains a serious public health concern—and it has exposed a critical gap in the world's vaccine arsenal.
Two approved Ebola vaccines already exist: Ervebo and the combination Zabdeno/Mvabea. Both work well against the Zaire strain of Ebola virus. But the virus spreading through the DRC and Uganda is different. The Bundibugyo virus has distinct surface proteins that the existing vaccines were not designed to recognize, rendering them ineffective against this particular outbreak. This mismatch is why the Coalition for Epidemic Preparedness Innovations announced up to $62 million in new funding this week to accelerate development of the first human vaccine specifically targeting Bundibugyo Ebola.
Three candidates are now in the pipeline, each taking a different scientific approach. The International AIDS Vaccine Initiative, working with the University of Texas Medical Branch, has developed a single-dose vaccine that uses technology similar to the approved Ervebo shot. It has shown promise in macaque monkeys, protecting them against Bundibugyo infection, but human trials remain seven to nine months away. A World Health Organization expert panel called this the most promising of the three candidates.
Moderna, the pharmaceutical company known for its COVID-19 mRNA vaccine, is developing an mRNA-based vaccine that targets the surface glycoprotein of the Bundibugyo virus. The new funding will support both animal studies and human clinical trials. The third candidate comes from the University of Oxford and the Serum Institute of India, built on the same viral vector technology used in the Oxford-AstraZeneca COVID vaccine. This group is further behind—testing has only just begun—but the WHO panel suggested human trials could start within two to three months if additional animal data supports the approach. If successful, a single dose might protect contacts of infected people, while healthcare workers and other high-risk groups might need two doses.
The path from promising laboratory results to a vaccine in people's arms is long and fraught with obstacles. Each candidate must prove safe and effective in human trials, navigate regulatory approval, be manufactured at scale, and then be transported and administered in regions that are often remote, under-resourced, and sometimes unstable. Recruiting volunteers for clinical trials presents its own challenge, particularly when misinformation about vaccines circulates and when trials must be conducted far from the affected populations. The later-stage trials that would confirm safety and efficacy typically happen in the outbreak region itself—precisely where logistical and security challenges are greatest.
For now, the outbreak remains under control primarily through basic infection prevention: isolation of the sick, protection of healthcare workers, and careful contact tracing. A vaccine would transform the response, offering a tool not just for this outbreak but for future Bundibugyo cases. But that tool does not yet exist. The race to create it has begun, and the funding is in place. What remains is the painstaking work of science, conducted under the pressure of an active outbreak and the weight of public health stakes.
Notable Quotes
A vaccine would make a significant difference in our ability to control this outbreak and would be a useful tool for protecting against and responding to future outbreaks of the Bundibugyo virus.— Paul Griffin, Professor of Infectious Diseases and Microbiology, University of Queensland
The Hearth Conversation Another angle on the story
Why does an existing Ebola vaccine not work here? Surely the virus is still Ebola.
It is, but Ebola isn't one virus—it's a family of them. The approved vaccines were built to recognize the surface proteins of the Zaire strain. Bundibugyo has different proteins. It's like having a key that opens one lock but not another, even though both are doors.
So we're starting from scratch?
Not entirely. The technology platforms—how to build the vaccine—already exist and have been proven. What's new is the target. We're adapting proven methods to a new virus.
The IAVI vaccine is called most promising. What makes it stand out?
It's a single dose, which matters for delivery in difficult settings. And it's already shown it can protect animals against this specific virus. The others are still in earlier stages of proof.
How long until people can actually get vaccinated?
If everything goes perfectly, the fastest candidate could enter human trials in two to three months. But human trials themselves take time—you need to show safety first, then efficacy. We're likely talking about a year or more before any vaccine is approved for use.
What's the hardest part of this whole process?
Not the science. It's the logistics and the trust. You need to run trials in places that are remote, sometimes dangerous, with limited infrastructure. And you need people to volunteer for a trial when there's already vaccine hesitancy and misinformation out there.
So the outbreak could be over before a vaccine is ready?
It's possible. Right now, the numbers are actually coming down—suspected cases dropped from over 1,000 to 344 confirmed. But that doesn't mean we stop. A vaccine is insurance against the next outbreak, and against this one spreading further.